Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 5, 2026 (7 months ago)

Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%* (Brimonidine Tartrate and Timolol Maleate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp. Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-0589-1.

Affected NDC 60505-0589-01

Compare with the code on your package — it is the most precise check available.

Drug: Timolol Category: Eye Drops & Ophthalmic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution
Brimonidine Tartrate and Timolol Maleate
NDC 60505-0589
BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL Solution
Ophthalmic
Apotex Corp. Rx
Recalling firm
Apotex Corp.
NDC code
60505-0589-1
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0407-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Timolol recalls

See all
Class II · Moderate risk

Timolol Maleate Ophthalmic Solution USP

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 64980-514-01 D-0403-2025

Other recalls by Apotex Corp.

All 2026 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026